Isabelle Ragueneau‐Majlessi

Research and Studies Telecommunications Centre

Also affiliated with Certara (United States)

Pharmacology, Toxicology and PharmaceuticsMedicineComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018”.

Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2259

N/A

0DataRank · unranked

16 citations

Xinning Yang, Jingjing Yu, Hristina Dimova, Shiew‐Mei Huang, Isabelle Ragueneau‐Majlessi +2 more

Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin

Clinical Therapeutics(2021)10.1016/j.clinthera.2021.08.016

N/A

0DataRank · unranked

4 citations

Claire Steinbronn, Jingjing Yu, Catherine K. Yeung, Isabelle Ragueneau‐Majlessi, Lindsay M. Henderson